Organic Active Ingredients TRIZ Cases

Combining a substituted pyrazole CDK4/6 inhibitor with endocrine therapy helps cut recurrence risk in HR+/HER2- early breast cancer.

A polysiloxane adhesive matrix with solubilizer and propylene glycol improves THC skin permeation and maintains continuous transdermal flux.

An AG5 andrographolide derivative suppresses multiple cytokines and neutrophil migration while avoiding the toxicity of antibody-based cytokine storm treatments.

A balanced crystalloid ammonium sulfate gradient boosts extracellular vesicle drug loading while avoiding precipitation and preserving exosome activity.

Salt conversion to a sulfate crystal improves MNK inhibitor solubility, lowers oxidation risk, and supports easier production and storage.

Novel cyclopentapyrrole and azabicycloheptane agonists improve orexin receptor targeting for potential treatment of neurological and psychiatric disorders.

Sulfonic acid counter-ions keep tranexamic acid ester salts uniformly dispersed in skin compositions without crystallization or added stabilizers.

Small-molecule GLP-1R modulators address the injection-to-oral tradeoff by preserving agonist activity for obesity, NASH, and Type 2 diabetes.

Reduced-pressure Maillard coating with de-oiled lecithin protects PUFAs from rumen biohydrogenation and improves milk and meat fatty acid profiles.

Irinotecan-loaded mesoporous silica nanoparticles target cancer cells to curb metastasis, improve delivery, and reduce side effects.

Nitrogen heterocyclic compounds covalently bind KRAS G12C, create a new pocket, and lock the protein in an inactive state for cancer treatment.

An alcohol-propylene glycol aqueous dronabinol solution improves room-temperature stability and delivers faster, more consistent oral absorption.

Selective topical PI3K/mTOR compounds improve skin penetration and stability while reducing systemic side effects in long-term skin disorder treatment.

Glyburide analog compositions enhance autophagy to clear misfolded protein aggregates and reduce cellular damage in autophagy-associated disease.

Combining a thioether-linked antibody-drug conjugate with paclitaxel or eribulin boosts antitumor activity by suppressing resistance factors.

Young watermelon compounds Citrulluside H and T reduce ROS, inhibit MMP-1 and AP-1 activity, and support safe anti-skin aging use.

Targeting the Nrf2/HO-1 axis with dimethyl or monomethyl fumarate boosts IL-10 and reduces macrophage activation syndrome symptoms.

Compounds that stabilize vascular endothelium help prevent hemorrhage, vascular instability, and blood-brain barrier disruption during thrombolytic therapy.

A stabilized oxazine HBr salt and in situ synthesis reduce harmful impurities, while a hydrochloride 1.5 hydrate stabilizes oral dosing.

Modified oligonucleotides lower thrombopoietin activity while keeping platelet counts in a safe range for disease management.

Targeted ADC depletion of recipient stem cells plus JAK inhibition enables alloHSCT engraftment with lower toxicity than chemotherapy or irradiation.

Combining magnesium salts or chelates with ascorbate improves GI absorption by at least 55% while reducing gastrointestinal side effects.

Selective and dual Factor XIa-plasma kallikrein inhibitors help control abnormal coagulation while improving thrombosis treatment flexibility.

Unnatural base pairs are incorporated in vivo to expand nucleic acid chemical diversity while preserving polymerase-compatible stability and function.

A solid GDL-HPMC vaginal tablet solves the instability of liquid gluconic acid while enabling slow release, biofilm reduction, and low side effects.

Selective caries removal, pulp capping, and staged follow-up relieve symptomatic pulpal pain while preserving vitality and avoiding overtreatment.

Selective M4 antagonists expand BFU-E progenitors to improve erythrocyte production in anemia cases where erythropoietin is ineffective.

Combining auristatin-based ADCs with PI3K-AKT-mTOR inhibitors overcomes pathway complexity to improve tumor cell killing and growth control.

Tetracyclic compounds act prophylactically and therapeutically against Zika virus, helping block infection and slow disease progression.

Using yeast ascospores as the chitosan source avoids shellfish contaminants and deacetylation, enabling cleaner production for food and therapeutic use.

Insoluble coating particles and a dilute binder form stable granules that resist segregation and keep mixtures uniform at high productivity.

Predetermined linker length and diameter help PSMA conjugates deliver therapeutic or imaging agents to prostate cancer cells while limiting off-target effects.

A low-GWP HFO-1234ze epinephrine MDI uses ethanol and polysorbate 80 to keep the suspension stable and delivery consistent.

Chemically modified APOC3 siRNA conjugates improve stability and sustain gene silencing to lower blood lipids in dyslipidemia.

HSD3B1 genotype and 3β-HSD1 protein testing guide corticosteroid or non-corticosteroid selection to reduce asthma under- and over-treatment.

Novel small-molecule Drp1 inhibitors improve selectivity and oral bioavailability while reducing mitochondrial fission linked to disease.

Targeting LTA4H with benzodioxane inhibitors modulates leukotriene production to improve cognition and reduce age-related neuroinflammation.

Lewis acid mediated coupling improves regioselective pyrimidinyl-4-aminopyrazole synthesis for LRRK2 inhibitor intermediates.

Swirling airflow rotates the capsule to aerosolize powder at smoking-like inhalation rates while the modular cavity supports easy capsule replacement.

Substituted indole compounds activate IDO1 and help preserve its ferrous activity in cells, improving immune regulation in autoimmune disorders.

A U7-based snRNA targets USH2A pre-mRNA to skip Exon 13 more precisely than AON, avoiding frameshift risk and easing large-gene delivery limits.

Preformed HDL-like nanodiscs protect peptides and nucleic acids from degradation while improving co-delivery to lymphoid tissues.

A base-catalyzed synthesis and controlled crystallization route raises Jaktinib dihydrochloride purity above 99.0% while limiting mutagenic impurities.

Novel AR-targeting PROTAC compounds use segmented ligands and linker tuning to improve solubility, metabolic stability, and AR degradation.

Controlled oral minoxidil release over 12 hours helps treat hair loss while lowering peak adverse effects and improving compliance.

A combined isoquercetin, vitamin B3, and vitamin C regimen inhibits PDI to reduce thrombo-inflammatory vasculopathy in sickle cell disease.

Cell membrane nanoparticles use an isotonic inner core plus steroid and sphingolipid enrichment to improve stability and therapeutic delivery.

Gene expression profiling of NRF2 splice variants and downstream targets helps identify NRF2-dependent cancers and guide antagonist-based treatment.

A topical midostaurin formulation lowers tyrosinase activity and melanin with less irritation and toxicity than conventional hyperpigmentation therapies.

Synthetic lysine analogs block CDCP1 cleavage and p300 acetylation to inhibit cancer cell proliferation, metastasis, and survival.